Background:
Introduction
In later life, lower body mass index (BMI), being underweight by definition, and declining BMI (despite one's BMI level at onset of decline), are associated with greater risk of late-onset dementias [1, 2] . In mid-or adult life, higher BMI is prospectively associated with dementia risk [1] . This difference in the mid-life versus latelife BMI-dementia risk association is often referred to as the 'obesity paradox' and evidence of reverse causality [3] .
Anthropometric characteristics are sculpted by amount and distribution of adipose tissue. Changes in this important tissue result from lifetime variations in energy balance, sociocultural background, and epigenetic phenomena, and develop secondarily to central pathophysiological changes in preclinical and clinical dementia [4] . Therefore, adiposity indicators like BMI, waist-hip ratio (WHR), and circulating blood levels of adipokines, such as leptin and adiponectin, are potential risk markers for dementia [5] [6] [7] [8] . Since adipose tissue is the primary source of both of these adipokines, leptin and adiponectin are good biomarkers of this tissue's metabolic activity.
There is limited and ambiguous published research regarding the link between adipokine levels and sporadic, late-onset dementias [9, 10] . However, leptin is associated with insulin resistance and brain health, [11, 12] and is the adipose tissue hormone [13] most studied in association with brain structure and function. Leptin has numerous effects on brain development [14] , and potentially on brain health in cognition and aging.
Peripheral leptin enters the central nervous system and interacts with specific areas of the brain such as the hypothalamus and hippocampus [15] . In addition to crossing the BBB [16] , several studies indicate that leptin is also produced in the brain, for example in the hypothalamus, cortex and cerebellum [17, 18] . Leptin has been prospectively associated with dementia over 8 years [19] , but not over 24 years, from mid-to latelife [20] . Leptin is positively correlated with total and central anthropometric adiposity measures [21, 22] .
Adiponectin is a visceral adipose tissue marker and exists as complex multimeric isoforms comprised of high molecular weight (HMW) hexamers and trimers [23] . It is an effective insulin sensitizer, and circulating levels are inversely correlated with insulin resistance, metabolic syndrome, adiposity, type 2 diabetes, and cardiovascular diseases. Adiponectin modulates inflammatory responses, energy expenditure (CNS and periphery), food intake (CNS), and a number of metabolic processes, including glucose regulation and fatty acid catabolism in the periphery. Since blood-brain barrier (BBB) transport mechanisms for adiponectin are unclear, blood levels may not indicate potential interactions between adiponectin and the brain [24] .
We investigated the association between dementia occurrence and both anthropometric and adipokine indicators of adiposity -BMI, WHR, and blood leptin and adiponectin levels -in a 10-year prospective population-based study of Swedish adults, aged 70 years and older. Moreover, we examined whether these adiposity markers predict dementia occurrence over the short-and/or long-term. This study will further reveal the complex interplay between surrogate markers of adiposity and dementia onset.
Methods

Participants
Participants comprising the Gothenburg Birth Cohort Studies, originate from two epidemiological studies in Gothenburg, Sweden: 1) the Prospective Population Study of Women (PPSW) and 2) the Gerontological and Geriatric Population Studies (H70). Both have been described in detail previously [25] [26] [27] . Eligible participants were sampled from the Swedish Population Register based on birth date. PPSW participants were born in 1908, 1914, 1918, 1922 and 1930 Those who died, or declined participation during follow-up, were traced in records from hospitals and homes for the aged, inpatient and outpatient departments in psychiatric hospitals and clinics, municipal psychiatric outpatient departments in Gothenburg, the hospital-linkage system, and death certificates [28] . All participants (or their closest relatives) gave informed consent, which was conducted in accordance to the provisions of the Helsinki Declaration. The study was approved by the Ethics Committee for Medical
Research at the University of Gothenburg.
Dementia assessment
Dementia diagnoses were made according to the Diagnostic and Statistical Manual of Mental Disorders 3rd
Edition Revised (DSM-III-R) [29, 30] A close informant interview was conducted using IQCode [31] . Symptom domains relevant for making a dementia diagnosis include: memory (short-term, long-term), aphasia (language disturbance), apraxia (inability to carry out motor activities despite intact function), agnosia (failure to identify or recognize objects despite intact sensory function), executive function (planning, organizing, abstract thinking) and personality changes (used in DSM-IIIR criteria for dementia, not in DSM-IV or DSM-V).
Participants must have evidenced significant impairment in social or occupational functioning representing significant decline from a previous level of functioning. There was also a global rating of symptom status made by the interviewer (psychiatrist or psychiatric nurse) and information from close informants related to dementia symptoms. The Comprehensive Psychiatric Rating Scale (CPRS) [32] , an extensive neuropsychiatric inventory, was used to rate psychiatric symptoms and signs at face-to-face examinations. The Mini-Mental Examination (MMSE) was used as an additional evaluation of global cognitive impairment, but is not considered diagnostic by itself. In addition, the Swedish Hospital Discharge Registry provided diagnostic information for individuals discharged from hospitals since 1978. Medical records were collected from hospitals and outpatient departments in Sweden's public health care system. Incident cases of dementia up to December 31, 2010 were also based on information from the Swedish Hospital Discharge Register (ICD-10: F00.1, F01.8, F01.9, F03.9, G30.9). Thus, dementia diagnoses were obtained for all study participants, since almost all people in Sweden receive health care from the community and have an equal chance of having a medical record. Dementia was diagnosed by neuropsychiatrists at consensus meetings based on all information sources available, e.g., neuropsychiatric examinations, medical records, and close informant interviews.
Anthropometric assessments
Anthropometric measurements were conducted in the morning when participants wore light clothing at each examination [33] . Body weight was recorded to the nearest 0.1 kg, and body height was measured to the nearest 0.5 cm. BMI was calculated as kg/m 2 . Waist and hip circumferences were measured to the nearest 0.5 cm. Measures of each were conducted until there was agreement within 0.5 cm.
Blood measures
Blood samples were collected after a 12-hour fast, and plasma aliquots stored at −70°C. Regarding baseline adipokine measures, control standards and participant samples were tested in duplicate using High genotyping was performed by mini-sequencing as previously described in detail [34] . Genotypes were obtained for the two SNPs (rs7412 and rs429358), which are used to unambiguously define ε2, ε3, and ε4 alleles.
Lifestyle assessments and medical history
Level of education (completing six years compulsory education or less vs at least compulsory education); socioeconomic status (SES, working vs middle/upper class); alcohol consumption and cigarette smoking (ever vs never use); medication use; and medical history were queried at each examination. Diagnoses of myocardial infarction, stroke, cancer, and diabetes were self-reported as well as determined by clinical examinations (ECG and blood samples), case records, hospital discharge registry, national cancer registry, and national stroke registry. Systolic (SBP) and diastolic blood pressures (DBP) were measured while participants were sitting down and at rest for at least 5 minutes. Depressive symptoms were measured using the Montgomery-Åsberg depression rating scale (MADRS) [35] .
Statistical analyses
Means and standard deviations were calculated for all continuous variables, and frequencies and Selection of covariates originated from a pool of potentially biologically relevant variables: age; sex; education; socioeconomic status (SES); smoking; alcohol intake; depressive symptoms; diabetes; cancer; heart attack; stroke/transient ischemic attack; hypertension; blood triglyceride, cholesterol, HDL, LDL, and glucose levels; DBP; SBP; and APOEε4 genotype. All potential covariates were included in age-adjusted logistic regression models predicting dementia over the entire follow-up period. Age, sex, SES, smoking status (ever/never), diabetes (yes/no), alcohol intake (ever/never), depressive symptoms (MADRS score > 12), and presence of at least one APOEε4 allele were significant at p≤0.05 and included in multivariable models. Two-tailed tests were used with a significance level of p≤0.05. SPSS, version 20.0 (IBM Corporation, Armonk, New York, USA), was used to perform data analyses.
Results
Overall, 924 adults (224 men and 700 women) without dementia, participated in the baseline (year 2000) examination. PPSW and H70 were representative of the population base with regard to sex; marital status; income; community rent allowance for those who could not afford housing; rate of inpatient and outpatient care in psychiatric hospitals, clinics, and municipal outpatient departments; and rates of registration with the Temperance Board (national registry for alcohol abuse). Over ten years, 134 participants developed dementia.
The average age of the participants at baseline (n=924) was 74.0 years, and when stratified by sex, the average age of men was 70.0 years and for women, 75.3 years (Table 1) . Compared to men, women were more likely to be underweight and had higher plasma levels of leptin and adiponectin. Approximately 25% of the study population had at least one APOEε4 allele (27.7% in men and 24.4% in women).
Multivariable logistic regression models were used to examine the relationship between continuous baseline adiposity indicators and subsequent dementias. No associations were found between BMI, WHR, leptin or adiponectin and dementia occurrence in the entire sample over the ten year follow up (Table 2 ; data not shown for adipokines).
To better understand the temporality of association between adiposity markers and dementia, we divided the ten year follow-up period into two five year dementia occurrence intervals -2000-2005 and 2005-2010 (Table 2) , as has been done previously [38] . When analyzed continuously, a higher baseline BMI lowered the odds of dementia within five years. However, using traditional BMI categories, participants with an 'underweight' BMI (< 20 kg/m 2 ) had higher odds of developing dementia compared to participants with a 'healthy' BMI (reference category BMI 20.00-24.9 kg/m 2 ) ( Table 2 ). This finding among underweight may have driven the protective association observed when BMI was modelled as a continuous variable. This association was driven by female participants (Table 2 ).
In women, we also found an association between leptin levels and odds of dementia within the first five 
Discussion
In an elderly Swedish sample of women and men, we observed that a low BMI (<20 kg/m2) was associated with over a 5-fold higher odds of developing dementia within five years in women, aged 70 years and older.
Given published literature on mid-life obesity and later onset dementia, this may be evidence of an obesity paradox and/or reverse causality. However, without mid-life measures, we cannot be sure. In addition, the odds of developing dementia were 70% lower in women aged 70 years and older who had intermediate serum leptin levels based on analysis of leptin quartiles. Thus, despite a robust correlation of r =0.71 between BMI and leptin in this sample, there is a suggestion that these adiposity indicators were differentially associated with development of dementia within 5 years of measurement in elderly women.
Other studies in middle-aged and elderly women have suggested contradictory associations between anthropometric versus leptin levels and cognition or dementia [10, 39, 40] .
Our analyses support a first-ever published report from the original Gothenburg Birth Cohort Study (H70) among those born 1901/02 [38] . Similar to the 2003 report, there was no association between higher BMI and dementia observed during the first 10 years of follow-up. In contrast to the 2003 report, the current analysis includes primarily those born 1930. Thus, with further follow-up, we will be able to observe a 30 year cohort comparison of the BMI-dementia association. In addition, we also chose to focus on all dementias, due to controversies and changes in the field regarding diagnoses of dementia subtypes without the use of neuroimaging or cerebrospinal fluid biomarkers [41] .
Our study has many advantages. First, the population sample is part of a long-standing series of rich longitudinal birth cohort studies in Sweden beginning in 1968 (PPSW) and 1971 (the first H70 cohort) [25, 26] , with consistent measures over time among unique birth cohorts. Second, there is long follow-up of a large sample of rigorously studied elderly, age 70 years and older, and adjustment for multiple potential confounders. Third, we measured blood levels of adipokines reflecting the metabolic activity of adipose tissue. Finally, we used the study design to our advantage, to estimate temporal (shorter versus longer term) associations of adiposity indicators with dementia. Given the important role of temporality in understanding risk and protective factor-dementia associations, we see this as a definite strength of these studies.
As with any study design, there are limitations. First, while data from the Gothenburg Birth Cohort Studies have been published using this merged sample examined with identical methods by the same research group at the same time [42, 43] , the study is unbalanced regarding sex and age. All men were aged 70 years at baseline, whereas women were aged 70 years and older. Thus, our observations regarding sex differences should be interpreted cautiously. Second, a small number of male participants reduced the power for analyzing associations in men given that dementia onset was monitored during a period of relatively low risk, notably the 8 th decade of life [38] . Third, leptin and adiponectin measures were only measured at baseline, thus repeated measures and change in these important hormones over time cannot be considered.
Fourth, other nutritional influencers of BMI and WHR, including estimates of energy intake and expenditure, are unavailable. Fifth, our leptin findings are rather conservative. While leptin has strong mechanistic actions in the brain, the use of this marker in the periphery as a reflection of the fat-brain axis remains unclear, especially at a life stage when there are ageing-related body composition changes. In addition, replication of our observations regarding leptin is essential. Finally, some may deem four and five year examination intervals to characterize date of dementia onset as unacceptable. However, given the insidious and often slowly progressive course of dementia onset and a population-based sample, we deem it highly acceptable for these types of analyses. Calculating odds ratios (OR), given this nuance, closely approximates the risk. We have shown this in a previous publication on adiposity measures and dementia [38] .
While we found that the odds of developing dementia are higher in elderly women with low BMI within five years, this is not a new finding. The association between BMI and dementia appears to change over the life course. Some studies show that adults with a high midlife BMI or central obesity have a higher risk of latelife dementia [1] . Others have reported that weight loss or BMI decline is associated with dementia risk in elderly [44, 45] . That low BMI may be a preclinical marker for dementia, is suggested by neuropathophysiological changes accompanying dementia. These changes can induce changes in body weight and adipose storage. For example, brain areas that control weight (i.e. mesial temporal cortex) are affected during the preclinical dementia phase; and adipose tissue loss may result from preclinical apathy, reduced olfactory function, difficulty with eating (e.g., aphasia), inadequate nutrition or prescribed medicines targeting dementia related symptoms e.g. depression or cognitive impairments [46] .
Furthermore, we found that the odds of developing dementia in elderly women were lower among those with intermediate blood leptin levels. Postmenopausal women may have a greater risk of developing dementia than men, perhaps due to changes in leptin and brain function due to a fall in endogenous estrogen levels following menopause [47] . Estrogen and leptin have neuroprotective effects on cognition by regulating neurogenesis, hippocampal synaptic plasticity, and axonal growth [11] . However, the roles of adipokines are diverse, and often enigmatic. The adiposity-dementia association, remains to be elucidated, as this is by no means clear.
As higher levels of adiposity, commonly measured as anthropometric overweight and obesity, are associated with higher risk for cardiovascular disease (CVD) [48, 49] , and CVD is a risk factor for dementia [50] , we explored CVD variables as potential covariates. None were significantly associated with dementia in ageadjusted models. This null observation associating dementia with CVD risk in late-life concurs with other published reports [51] . In addition, adiponectin, known to be associated with CVD, was not associated with dementia.
The underlying neurodegenerative and vascular pathologies observed in dementia, and subsequent impairment of key fat-brain and gut-brain feedback loops [52] , may be at the root of conflicting observations; and seemingly intertwined adiposity factors may be differentially associated with dementia when measured within five years. Our findings are supported by studies reporting that higher levels of leptin are prospectively associated with lower odds of dementia or mild-cognitive impairment in elderly [10, 53, 54] . Metabolic dysregulation may accompany or promote late-life alternations in leptin levels and dementias [55] . Atrophy of the posterior hypothalamus affects appetite and feeding behavior via disintegration of network connections and effects on hormone synthesis [55, 56] . In addition, higher levels of leptin are observed to be neuroprotective [57] . 
Conclusion
